DNLI Q1 2020 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-14.3% YoY

Gross Profit

$4M100.0% margin

Operating Income

-$60M-1663.9% margin

Net Income

-$57M-1575.0% margin

EPS (Diluted)

$-0.55

QoQ Revenue Growth

-22.9%

Cash Flow

Operating Cash Flow

-$54M

Free Cash Flow

-$55M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$696M

Total Liabilities

$151M

Stockholders' Equity

$545M

Cash & Equivalents

$208M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$4M	-14.3%
Gross Profit	$4M	$4M	-14.3%
Operating Income	-$60M	-$43M	-41.1%
Net Income	-$57M	-$39M	-45.6%

Revenue Segments

Alzheimer's Disease Services

$3M100%